Elacestrant

EMERALD

Elacestrant EMERALD

PRELIMINARY SCORE

CURATIVE

NON-CURATIVE

PFS

ADJUSTMENTS

Quality of life

QoL data pending

Serious and disabling adverse effects

Other adjustments

Elacestrant EMERALD

SCORE

CURATIVE

Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE

Overall Survival

3

Progression-Free Survival

Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate

Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Therapeutic Indication: Treatment of postmenopausal women, and men, with estrogen receptor (ER)-positive, HER2-negative, locally advanced or metastatic breast cancer with an activating ESR1 mutation who have disease progression following at least one line of endocrine therapy including a CDK 4/6 inhibitor
Experimental Arm: Elacestrant
Control Arm: Standard-of-care endocrine therapy